DNA Link Inc
KOSDAQ:127120
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.6), the stock would be worth ₩2 208.96 (95% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 71 | ₩44 000 |
0%
|
| 3-Year Average | 3.6 | ₩2 208.96 |
-95%
|
| 5-Year Average | 3.3 | ₩2 021.55 |
-95%
|
| Industry Average | 19.5 | ₩12 085.94 |
-73%
|
| Country Average | 1.3 | ₩796.09 |
-98%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
D
|
DNA Link Inc
KOSDAQ:127120
|
1.4T KRW | 71 | -85.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 6.6 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 6.1 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.8 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 3.5 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.3 |
| 70th Percentile | 2.8 |
| Max | 96 381.4 |
Other Multiples
DNA Link Inc
Glance View
DNA Link, Inc. provides genomic analysis services. The company is headquartered in Seoul, Seoul. The company went IPO on 2011-12-26. The firm provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The firm also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).
